NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease

RecruitingN/A

Sponsor: Vertero Therapeutics

Conditions: Parkinsons Disease (PD)

Countries: Netherlands

This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.

Eligibility overview

Sex: ALL

Age: 18 Years to 80 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Between 18-80 years of age at ICF signing (inclusive)
* A diagnosis of PD within 10 years from the time of ICF signing
* Current or history of gastrointestinal (GI) dysfunction or constipation based on screening assessment
* All participants must understand and provide written informed consent prior to any study specific procedures
* Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments

Exclusion Criteria:

* Any known GI disorder if deemed clinically significant by the investigator. GI disorders may include, but are not limited to: Crohn's disease, ulcerative colitis, celiac disease, irritable bowel syndrome, or lactose intolerance
* Recent GI infection in the past 3 months if deemed clinically significant by the investigator.
* Major GI surgery (excluding appendectomy/cholecystectomy), such as bariatric surgery, gastrectomy, esophagectomy, vagotomy, small intestine surgeries, any type of colectomy, colostomy and anorectal surgeries if deemed clinically significant by the investigator
* Any known current or past eating disorder if deemed clinically significant by the investigator
* Use of systemic antibiotics within 30 days prior to enrollment

Locations (1)

Leiden, Netherlands